Considering all the above data, in this study, the antileukemic effects of an MCL-1 inhibitor, S63845, were examined in human AML cell lines when used as a single agent or in combination with BCL-2/BCL-XL inhibitor, ABT-737. The gene discussed is BCL2; the disease is acute myeloid leukemia.